Get started

Financials · XLO

Xilio Therapeutics Inc. (XLO) financials

For the twelve months ended Sep 30, 2026, Xilio Therapeutics Inc. reported $55.01M of revenue and -$11.49M of net income.

Revenue, TTM
$55.01M
Revenue growth, YoY
+73.0%
Net income, TTM
-$11.49M
Net margin
-20.9%
Free cash flow, TTM
-$57.63M
Cash
$122.18M
P/S
1.04
Market cap
$57.0M
Annual revenue$43.77M
FY2024FY2025
Annual net income-$35.04M
FY2020FY2025
Annual free cash flow-$5.51M
FY2020FY2025

XLO revenue and earnings growth

XLO revenueQ3 2026$9.98M

Quarter YoY
-47.6%
QoQ
-46.6%
FY YoY
+589.9%

XLO revenue was $9.98M in fiscal Q3 2026 (ended Sep 30, 2026), down 47.6% from a year earlier and down 46.6% from the prior quarter. For the full fiscal 2025 it was $43.77M, up 589.9% from fiscal 2024.

XLO net incomeQ3 2026-$5.95M

XLO net income was -$5.95M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$16.29M a year earlier. For the full fiscal 2025 it was -$35.04M, compared with -$58.24M in fiscal 2024.

XLO EPSQ3 2026-$0.30

XLO diluted EPS was -$0.30 in fiscal Q3 2026 (ended Sep 30, 2026). For the full fiscal 2025 it was -$4.19.

XLO free cash flowQ3 2026-$13.85M

XLO free cash flow was -$13.85M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$17.50M a year earlier. For the full fiscal 2025 it was -$5.51M, compared with -$18.41M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
Revenue$43.77M$6.34M----
Research and development$56.04M$41.21M$52.14M$59.20M$51.19M$43.91M
Selling, general and admin$29.71M$24.78M$27.00M$29.95M$23.86M$10.65M
Operating income-$41.98M-$60.58M-$79.13M-$89.15M-$75.04M-$54.56M
Pre-tax income-$35.04M-$58.24M----
Income tax$0$0$0$0$0$0
Net income-$35.04M-$58.24M-$76.40M-$88.22M-$75.80M-$55.22M
EPS, basic-$4.19-$15.24-$38.92-$45.08-$189.28-$1475.88
EPS, diluted-$4.19-$15.24-$38.92-$45.08-$189.28-$1475.88

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
Cash and equivalents$137.53M$57.07M$46.29M$121.95M$199.61M$20.79M
Current assets$145.03M$60.23M$48.13M$124.50M$202.52M$20.59M
Total assets$154.69M$71.08M$60.93M$139.16M$218.06M$36.32M
Current liabilities$56.27M$27.26M$15.96M$21.12M$12.78M$22.16M
Total liabilities$119.41M$53.48M$24.10M$33.52M$32.63M$41.60M
Shareholders' equity$35.27M$17.60M$36.83M$105.65M$185.43M-$83.29M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
Operating cash flow-$4.99M-$18.38M-$68.62M-$75.72M-$80.75M-$36.09M
Capital expenditures$518.0K$36.0K$486.0K$1.87M$1.10M$2.19M
Free cash flow-$5.51M-$18.41M-$69.11M-$77.59M-$81.85M-$38.28M
Investing cash flow-$518.0K-$36.0K-$486.0K-$1.87M-$1.10M-$2.19M
Financing cash flow$87.78M$29.20M-$6.55M-$69.0K$260.67M$10.03M
Stock-based compensation$6.94M$6.43M$7.38M$8.42M$4.96M$1.30M
Depreciation and amortization$1.54M$1.64M$1.90M$1.85M$1.50M$1.06M

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
Revenue growth, YoY589.9%-----
Operating margin-95.9%-954.9%----
Net margin-80.1%-918.0%----
Free cash flow margin-12.6%-290.3%----
Return on equity-99.3%-331.0%-207.5%-83.5%-40.9%-
Return on assets-22.6%-81.9%-125.4%-63.4%-34.8%-152.0%
Current ratio2.582.213.025.8915.850.93

Source: XBRL data Xilio Therapeutics Inc. files with the SEC, latest filing dated Nov 10, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures and share counts are restated for stock splits the filings show: 1-for-14, first reported Mar 23, 2026.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

XLO peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
XLO$55.01M+73.0%-$11.49M-20.9%$57.0M
LLY$86.46B+45.5%$27.58B31.9%$1.36T
JNJ$99.33B+7.8%$16.09B16.2%$687.89B
ABBV$66.01B+10.7%$10.34B15.7%$521.50B
MRK$67.38B+4.9%$2.45B3.6%$364.26B
NVS$54.53B+8.4%$13.98B25.6%$306.26B
AZN$58.74B+8.6%$10.22B17.4%$286.03B
ABT$48.23B+10.0%$4.70B9.7%$187.95B
NVODKK 309.06B+6.4%DKK 102.43B33.1%$184.33B

XLO FAQ

7 questions
  • What is XLO revenue?
    Xilio Therapeutics Inc. (XLO) reported $55.01M of revenue for the twelve months ended Sep 30, 2026. That is up 73.0% from the year before. Revenue for fiscal 2025 was $43.77M.
  • Is XLO profitable?
    No. Xilio Therapeutics Inc. reported a net loss of $11.49M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does XLO have?
    Xilio Therapeutics Inc. reported $122.18M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is XLO revenue growing?
    Xilio Therapeutics Inc.'s revenue changed +589.9% in fiscal 2025, to $43.77M.
  • What is XLO free cash flow?
    Xilio Therapeutics Inc. generated -$57.63M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of -$56.90M less capital expenditures.
  • When did XLO last report financial results?
    The latest statements here come from Xilio Therapeutics Inc.'s 10-Q filed on Nov 10, 2026, covering the period ended Sep 30, 2026.
  • Where does this XLO financial data come from?
    Quantisnow builds these statements from the structured XBRL data Xilio Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.